Literature DB >> 1438661

Prevalence of psychiatric disorders in early stages of HIV infection.

G R Brown1, J R Rundell, S E McManis, S N Kendall, R Zachary, L Temoshok.   

Abstract

As part of a military universal HIV screening program, 442 men were assessed for the presence of DSM-III-R defined psychiatric disorders and symptoms of anxiety and depression after notification of HIV seroconversion. Of them, 84.4% were in the earliest, asymptomatic stages of disease at the time of interview (96% did not have AIDS). The Structured Clinical Interview for DSM-III-R and Structured Interview Guide for the Hamilton Anxiety and Depression Scales were used. Relevant comparisons were made to Epidemiologic Catchment Area prevalence data. HIV seropositive men were more likely than age-matched men in the community to have current diagnoses of major depression (ages 18-44) and anxiety disorders (ages 25-44). Higher lifetime rates of major depression and alcohol use disorder, and high current prevalence of sexual dysfunction (21.7%) were noted. We conclude that men who become HIV seropositive have high rates of mood and substance use disorders prior to knowledge of seroconversion, and that early in the course of HIV infection men are at risk for developing major depression, anxiety disorders, and disorders of sexual desire.

Entities:  

Mesh:

Year:  1992        PMID: 1438661     DOI: 10.1097/00006842-199209000-00006

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  14 in total

1.  Alcohol consumption enhances antiretroviral painful peripheral neuropathy by mitochondrial mechanisms.

Authors:  Luiz F Ferrari; Jon D Levine
Journal:  Eur J Neurosci       Date:  2010-08-19       Impact factor: 3.386

2.  Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States.

Authors:  Bryan Hartzler; Julia C Dombrowski; Heidi M Crane; Joseph J Eron; Elvin H Geng; W Christopher Mathews; Kenneth H Mayer; Richard D Moore; Michael J Mugavero; Sonia Napravnik; Benigno Rodriguez; Dennis M Donovan
Journal:  AIDS Behav       Date:  2017-04

Review 3.  [Clinical features, diagnosis and treatment of HIV-induced neuropsychiatric disorders].

Authors:  Hans-Bernd Rothenhäusler
Journal:  Wien Med Wochenschr       Date:  2006-12

4.  HIV Prevalence Among Hospitalized Patients at the Main Psychiatric Referral Hospital in Botswana.

Authors:  Philip R Opondo; Ari R Ho-Foster; James Ayugi; Bechedza Hatitchki; Margo Pumar; Warren B Bilker; Michael E Thase; John B Jemmott; Michael B Blank; Dwight L Evans
Journal:  AIDS Behav       Date:  2018-05

5.  Hippocampal volume mediates the relationship between measures of pre-treatment cocaine use and within-treatment cocaine abstinence.

Authors:  Jiansong Xu; Hedy Kober; Xin Wang; Elise E DeVito; Kathleen M Carroll; Marc N Potenza
Journal:  Drug Alcohol Depend       Date:  2014-07-17       Impact factor: 4.492

6.  Risks for HIV infection among users and sellers of crack, powder cocaine and heroin in central Harlem: implications for interventions.

Authors:  W Rees Davis; B D Johnson; D Randolph; H J Liberty
Journal:  AIDS Care       Date:  2006-02

7.  Risk of psychiatric disorders among individuals reporting same-sex sexual partners in the National Comorbidity Survey.

Authors:  S E Gilman; S D Cochran; V M Mays; M Hughes; D Ostrow; R C Kessler
Journal:  Am J Public Health       Date:  2001-06       Impact factor: 9.308

Review 8.  Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy.

Authors:  Geetanjali Chander; Seth Himelhoch; Richard D Moore
Journal:  Drugs       Date:  2006       Impact factor: 9.546

9.  Fourth revolution in psychiatry - Addressing comorbidity with chronic physical disorders.

Authors:  Shiv Gautam
Journal:  Indian J Psychiatry       Date:  2010-07       Impact factor: 1.759

10.  The impact of alcohol use on depressive symptoms in human immunodeficiency virus-infected patients.

Authors:  Lynn E Sullivan; Richard Saitz; Debbie M Cheng; Howard Libman; David Nunes; Jeffrey H Samet
Journal:  Addiction       Date:  2008-07-10       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.